2The Center for Genome Architecture, Baylor College of Medicine, Houston, TX 77030, USA.
3Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
4Center for Theoretical Biological Physics, Rice University, Houston, TX 77005, USA.
5Division of Cell Biology, Oncode Institute, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
6Division of Gene Regulation, Oncode Institute, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
7Department of Physics, Institute of Biosciences, Letters and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto – SP, 15054-000, Brazil.
8BioImaging Facility, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
9Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech, Pudong 201210, China.
Fox News Flash top headlines are here. Check out what s clicking on Foxnews.com.
Scientists are making dramatic strides toward a goal that once seemed almost unimaginable: Restoring limited vision to people affected by a previously irreversible form of blindness caused by an inherited eye disease called retinitis pigmentosa.
In a paper published Monday in the journal Nature Medicine, researchers working with the Paris-based company GenSight Biologics SA reported that a 58-year-old man who was diagnosed with retinitis pigmentosa 40 years ago was able to locate objects placed on a table after receiving an experimental therapy. And New York City-based company Bionic Sight LLC announced in March that four blind people in an early-stage clinical trial are now able to detect light and motion after undergoing a similar treatment. Those results haven’t yet been published.
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.
This 30-year collaboration is unique in its longevity and open scientific exchange.
Aiming to accelerate the translation of scientific discoveries into improved cancer therapies, Dana-Farber Cancer Institute and Novartis have renewed a longstanding research collaboration and – for the first time – are inviting grant applications from a broad range of Boston academic medical institutions. Under this renewal, more than $11 million will be available annually for research funding through the Dana-Farber/Novartis Drug Discovery and Translational Research Program (DDTRP).
The collaboration, which began in 1992, brings together scientists from Dana-Farber and Novartis to work on drug discovery and development efforts and has supported more than 700 research projects since inception.